IMMUNOTHERAPY: The development of immunotherapy in urothelial bladder cancer

    loading  Checking for direct PDF access through Ovid

Abstract

Recent data indicate that immune-checkpoint inhibitors have activity in patients with chemotherapy-refractory metastatic urothelial bladder cancer and further confirmatory trials are ongoing. Future research, including development of informative biomarker assessments, investigation of combination therapy and testing agents at earlier stages of disease is required to further explore this potential benefit.

Related Topics

    loading  Loading Related Articles